{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:59:52Z","timestamp":1790431192313,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T00:00:00Z","timestamp":1553817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.phrs.2019.03.017","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T14:18:35Z","timestamp":1553177915000},"page":"166-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Anticoagulant selection for patients with VTE\u2014Evidence from a systematic literature review of network meta-analyses"],"prefix":"10.1016","volume":"143","author":[{"given":"Alexander T.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha E.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du\u0161an","family":"Milenkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7927-8678","authenticated-orcid":false,"given":"Nathan R.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6899-007X","authenticated-orcid":false,"given":"Steven","family":"Lister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.phrs.2019.03.017_bib0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"43","key":"10.1016\/j.phrs.2019.03.017_bib0010","first-page":"3033","article-title":"ESC guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and management of acute pulmonary embolism of the european society of cardiology (ESC) endorsed by the european respiratory society (ERS)","volume":"35","author":"Members","year":"2014","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.phrs.2019.03.017_bib0015","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.phrs.2019.03.017_bib0020","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.phrs.2019.03.017_bib0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.017_bib0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11239-016-1446-0","article-title":"Vitamin K antagonists: relative strengths and weaknesses vs. Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation","volume":"43","author":"Zirlik","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"issue":"9","key":"10.1016\/j.phrs.2019.03.017_bib0035","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.phrs.2019.03.017_bib0040","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","article-title":"Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study","volume":"6","author":"Botticelli Investigators","year":"2008","journal-title":"J. Thromb. Haemost."},{"issue":"24","key":"10.1016\/j.phrs.2019.03.017_bib0045","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.phrs.2019.03.017_bib0050","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.phrs.2019.03.017_bib0055","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"VTEI","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.017_bib0060","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","article-title":"A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein\u2013DVT Dose-Ranging Study","volume":"112","author":"Buller","year":"2008","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.phrs.2019.03.017_bib0065","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Investigators","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.phrs.2019.03.017_bib0070","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Investigators","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.phrs.2019.03.017_bib0075","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.phrs.2019.03.017_bib0080","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of Dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.phrs.2019.03.017_bib0085","doi-asserted-by":"crossref","first-page":"LBA-2","DOI":"10.1182\/blood.V114.22.LBA-2.LBA-2","article-title":"Once-Daily Oral Rivaroxaban Versus Placebo in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism. the Einstein-Extension Study","volume":"114","author":"Buller","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.phrs.2019.03.017_bib0090","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1111\/j.1538-7836.2010.04016.x","article-title":"Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy","volume":"8","author":"Linkins","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.phrs.2019.03.017_bib0095","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2019.03.017_bib0100","volume":"Vol 4","author":"Higgins","year":"2011"},{"key":"10.1016\/j.phrs.2019.03.017_bib0105","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.017_bib0110","first-page":"301","article-title":"Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis","volume":"33","author":"Alotaibi","year":"2014","journal-title":"Int. Angiol."},{"key":"10.1016\/j.phrs.2019.03.017_bib0115","doi-asserted-by":"crossref","first-page":"f5133","DOI":"10.1136\/bmj.f5133","article-title":"Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis","volume":"347","author":"Castellucci","year":"2013","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.phrs.2019.03.017_bib0120","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jama.2014.10538","article-title":"Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis","volume":"312","author":"Castellucci","year":"2014","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.phrs.2019.03.017_bib0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160064","article-title":"Comparison of the Non-VKA oral anticoagulants apixaban, Dabigatran, and rivaroxaban in the extended treatment and prevention of venous thromboembolism: systematic review and network meta-analysis","volume":"11","author":"Cohen","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.phrs.2019.03.017_bib0130","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1024\/0301-1526\/a000373","article-title":"New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons","volume":"43","author":"Hirschl","year":"2014","journal-title":"Vasa"},{"issue":"6","key":"10.1016\/j.phrs.2019.03.017_bib0135","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.thromres.2014.03.035","article-title":"Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism","volume":"133","author":"Kang","year":"2014","journal-title":"Thromb. Res."},{"issue":"10","key":"10.1016\/j.phrs.2019.03.017_bib0140","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.clinthera.2014.06.033","article-title":"Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach","volume":"36","author":"Rollins","year":"2014","journal-title":"Clin. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.017_bib0145","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.thromres.2015.02.032","article-title":"Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis","volume":"135","author":"Sobieraj","year":"2015","journal-title":"Thromb. Res."},{"issue":"March(9)","key":"10.1016\/j.phrs.2019.03.017_bib0150","first-page":"1","article-title":"Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis","volume":"21","author":"Sterne","year":"2017","journal-title":"Health Technology Assessment in Winchester, England"},{"issue":"11","key":"10.1016\/j.phrs.2019.03.017_bib0155","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-139-11-200312020-00007","article-title":"Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis","volume":"139","author":"Linkins","year":"2003","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.017_bib0160","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1160\/TH08-03-0193","article-title":"Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry","volume":"100","author":"Ruiz-Gimenez","year":"2008","journal-title":"Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.phrs.2019.03.017_bib0165","doi-asserted-by":"crossref","first-page":"578","DOI":"10.7326\/0003-4819-152-9-201005040-00008","article-title":"Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism","volume":"152","author":"Carrier","year":"2010","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.017_bib0170","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/MAJ.0000000000000349","article-title":"Physician\u2019s fear of anticoagulant therapy in nonvalvular atrial fibrillation","volume":"348","author":"Sen","year":"2014","journal-title":"Am. J. Med. Sci."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.017_bib0175","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s12325-014-0119-7","article-title":"Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results","volume":"31","author":"Cohen","year":"2014","journal-title":"Adv. Ther."},{"issue":"8","key":"10.1016\/j.phrs.2019.03.017_bib0180","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jacc.2012.03.019","article-title":"Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation","volume":"60","author":"Lip","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.017_bib0185","first-page":"476","article-title":"An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation","volume":"108","author":"Mantha","year":"2012","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.017_bib0190","first-page":"981","article-title":"Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis","volume":"111","author":"Skjoth","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.phrs.2019.03.017_bib0195","doi-asserted-by":"crossref","first-page":"e7097","DOI":"10.1136\/bmj.e7097","article-title":"Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis","volume":"345","author":"Rasmussen","year":"2012","journal-title":"Bmj"},{"issue":"11","key":"10.1016\/j.phrs.2019.03.017_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(18)30816-7","article-title":"Comparison of effectiveness, safety, and the net clinical outcome between different direct oral anticoagulants in 162,707 non-valvular atrial fibrillation patients treated in us clinical practice","volume":"71","author":"Deitelzweig","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2019.03.017_bib0205","doi-asserted-by":"crossref","first-page":"k585","DOI":"10.1136\/bmj.k585","article-title":"Living network meta-analysis compared with pairwise meta-analysis in comparative effectiveness research: empirical study","volume":"360","author":"Nikolakopoulou","year":"2018","journal-title":"BMJ."},{"issue":"11","key":"10.1016\/j.phrs.2019.03.017_bib0210","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00296-014-2994-2","article-title":"Network meta-analysis for comparing treatment effects of multiple interventions: an introduction","volume":"34","author":"Catal\u00e1-L\u00f3pez","year":"2014","journal-title":"Rheumatol. Int."},{"issue":"08","key":"10.1016\/j.phrs.2019.03.017_bib0215","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.recesp.2013.11.016","article-title":"The transitive property across randomized controlled trials: if B is better than A, and C is better than B, will C be better than A?","volume":"67","author":"Catal\u00e1-L\u00f3pez","year":"2014","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.phrs.2019.03.017_bib0220","doi-asserted-by":"crossref","first-page":"d4909","DOI":"10.1136\/bmj.d4909","article-title":"Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study","volume":"343","author":"Song","year":"2011","journal-title":"BMJ"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818318425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818318425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:59:57Z","timestamp":1760911197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818318425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":44,"alternative-id":["S1043661818318425"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.03.017","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulant selection for patients with VTE\u2014Evidence from a systematic literature review of network meta-analyses","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}